文献速递冠心病

STEMI合并多支病变完全血运重建的最优策略:网络Meta分析

Optimal Strategy for Complete Revascularization in ST-Segment Elevation Myocardial Infarction and Multivessel Disease: A Network Meta-Analysis.
PubMed 文献 · J Am Coll Cardiol · 2025-01-01

该网络Meta分析纳入26项随机试验共15,902例STEMI合并多支病变患者,比较完全血运重建(CR)与仅罪犯血管血运重建及CR时机。结果显示立即CR和分期CR均优于仅罪犯血管治疗,且立即CR较分期CR进一步降低MACE,但排除操作性心梗后获益减弱。

要点

  • 立即CR和分期CR均较仅罪犯血管治疗降低MACE,无论造影或功能学指导。
  • 立即CR较分期CR降低MACE,主要源于心肌梗死减少。
  • 排除操作性心梗后,立即CR较分期CR的心梗获益减弱。

核心结论

  • STEMI合并多支病变患者中,立即或分期CR均优于仅罪犯血管治疗。
  • 立即CR较分期CR降低MACE,但排除操作性心梗后心梗获益减弱。

研究设计与样本

  • 网络Meta分析,检索PUBMED和EMBASE至2024年7月,纳入26项随机试验共15,902例患者。
  • 平均加权随访25.2±15.7个月,主要终点为MACE。

主要发现

  • 与仅罪犯血管治疗相比,立即CR的MACE RR为0.48(95%CI 0.36-0.64),分期CR的RR为0.65(95%CI 0.52-0.82)。
  • 立即CR较分期CR的MACE RR为0.74(95%CI 0.56-0.97)。
  • 造影指导亚组立即CR较分期CR的RR为0.77(95%CI 0.61-0.99),功能学指导亚组RR为0.49(95%CI 0.27-0.89)。
  • 包含操作性心梗时立即CR较分期CR的心梗RR为0.44(95%CI 0.27-0.71),排除操作性心梗后RR为0.65(95%CI 0.36-1.16)。

临床怎么用

  • STEMI合并多支病变患者应优先考虑完全血运重建,而非仅处理罪犯血管。
  • 立即CR可作为优选策略,但需注意其心梗获益部分源于操作性心梗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease, most but not all randomized trials have reported that complete revascularization (CR) offers advantages over culprit vessel-only revascularization. In addition, the optimal timing and assessment methods for CR remain undetermined. OBJECTIVES: The purpose of this study was to identify the optimal revascularization strategy in patients with STEMI and multivessel disease, using a network meta-analysis of randomized controlled trials. METHODS: We searched PUBMED and EMBASE for randomized trials evaluating revascularization strategies in patients with STEMI and multivessel disease through July 2024. A network meta-analysis was performed analyzing CR vs culprit vessel-only revascularization as well as the timing of CR (immediate CR vs staged CR). Outcomes were also assessed with 4 CR strategies based on whether revascularization was immediate or staged and whether it was angiographically guided or functionally guided. The primary outcome was major adverse cardiovascular events (MACE). RESULTS: A total of 26 randomized trials that enrolled 15,902 patients were included. The mean weighted duration of follow-up was 25.2 ± 15.7 months. MACE was reduced with both immediate CR and staged CR compared with culprit-vessel-only treatment (RR: 0.48; 95% CI: 0.36-0.64 and RR: 0.65; 95% CI: 0.52-0.82, respectively), whether with angiographic or functional guidance. Immediate CR was associated with reduced MACE compared with staged CR (RR: 0.74; 95% CI: 0.56-0.97), whether CR was guided angiographically or functionally (RR: 0.77; 95% CI: 0.61-0.99 and RR: 0.49; 95% CI: 0.27-0.89, respectively) caused by reductions in MI. However, when the analysis was restricted to studies that reported both all MI and nonprocedural MI, the benefit of immediate CR in reducing MI compared with staged CR was diminished after excluding procedural MI (RR: 0.44; 95% CI: 0.27-0.71 with procedural MI vs RR: 0.65; 95% CI: 0.36-1.16 without procedural MI). CONCLUSIONS: Among patients with STEMI and multivessel disease, outcomes were better with immediate or staged CR compared with culprit vessel-only treatment, whether with angiographic or functional guidance.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Ueyama, Akita, Kiyohara, et al. Optimal Strategy for Complete Revascularization in ST-Segment Elevation Myocardial Infarction and Multivessel Disease: A Network Meta-Analysis. J Am Coll Cardiol. 2025. PMID: 39779054. doi:10.1016/j.jacc.2024.09.1231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。